Application of precipitation methods for the production of water-insoluble drug nanocrystals: Production techniques and stability of nanocrystals

Current Pharmaceutical Design

Volumn 20, Issue 3, 2014, Pages 408-435

  Xia, Dengning ^a,b   Gan, Yong ^b   Cui, Fude ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anti solvent; Crystal grow and nucleation; Flash precipitation; Nanocrystals; Precipitation; Stability; Stabilizer; Supercritical anti solvent; Water insoluble drug

Indexed keywords

CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; EQUIPMENT DESIGN; MODELS, CHEMICAL; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 84894038195     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990397     Document Type: Review

References (221)

1. Kesisoglou F, Panmai S, Wu Y. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv Drug Delivery Rev 2007; 59: 631-44.
2. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-96.
3. Xia DN, Cui FD, Piao HZ, et al. Effect of Crystal Size on the In vitro Dissolution and Oral Absorption of Nitrendipine in Rats. Pharm Res 2010; 27: 1965-76.
4. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006; 62: 3-16.
5. Verma S, Gokhale R, Burgess DJ. A comparative study of topdown and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009; 380: 216-22.
6. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
7. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorlywater soluble compounds using wet media milling technology. Adv. Drug Delivery Rev 2011; 63: 427-40.
8. Chan HK, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Delivery Rev 2011; 63: 406-16.
9. Mullin JW ed. Crystallization (Fourth Edition). Butterworth-Heimemann: Oxford 2001.
10. Hornedo Nr, Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 1999; 88: 651-60.
11. Sue K, Usami T, Arai K, Kasai H, Nakanishi H, Hiaki T. Sizecontrolled production of quinacridone nanocrystals using hot compressed water recrystallization method. Dyes Pigm 2008; 76: 632-5.
12. Sugimoto T. Underlying mechanisms in size control of uniform nanoparticles. J Colloid Interface Sci 2007; 309: 106-18.
13. Lindfors L, Forssén S, Westergren J, Olsson U. Nucleation and crystal growth in supersaturated solutions of a model drug. J Colloid Interface Sci 2008; 325: 404-13.
14. Jones AG ed. Crystallization Process Systems. Butterworth-Heinemann: Oxford 2002.
15. Schuth F. Nucleation and crystallization of solids from solution. Curr Opin Solid St M 2001; 5: 389-95.
16. Erdemir D, Lee AY, Myerson AS. Nucleation of crystals from solution: classical and two-step models. Acc Chem Res 2009; 42: 621-9.
17. Dalvi SV, Dave RN. Analysis of nucleation kinetics of poorly water-soluble drugs in presence of ultrasound and hydroxypropyl methyl cellulose during antisolvent precipitation. Int J Pharm 2010; 387: 172-9.
18. Anderson VJ, Lekkerkerker HNW. Insights into phase transition kinetics from colloid science. Nature 2002; 416: 811-5.
19. Kashchiev D, Vekilov PG, Kolomeisky AB. Kinetics of two-step nucleation of crystals. JChPh 2005; 122.
20. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Controlled antisolvent precipitation of spironolactone nanoparticles by impingement mixing. Int J Pharm 2011; 410: 175-9.
21. Vekilov PG. The two-step mechanism of nucleation of crystals in solution. Nanoscale 2010; 2: 2346-57.
22. Vekilov PG. Nucleation. Cryst. Growth Des 2010; 10: 5007-19.
23. Lamer VK, Dinegar RH. Theory, Production and Mechanism of Formation of Monodispersed Hydrosols. J Am Chem Soc 1950; 72: 4847-54.
24. Diao Y, Helgeson ME, Myerson AS, Hatton TA, Doyle PS, Trout BL. Controlled nucleation from solution using polymer microgels. J Am Chem Soc 2011; 133: 3756-9.
25. Abu Bakar MR, Nagy ZK, Saleemi AN, Rielly CD. The Impact of Direct Nucleation Control on Crystal Size Distribution in Pharmaceutical Crystallization Processes. Cryst Growth Des 2009; 9: 1378-84.
26. Sugimoto T, Shiba F, Sekiguchi T, Itoh H. Spontaneous nucleation of monodisperse silver halide particles from homogeneous gelatin solution I: silver chloride. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2000; 164: 183-203.
27. Li X, Wang J, Shen Z, Zhang P, Chen J, Yun J. Preparation of uniform prednisolone microcrystals by a controlled microprecipitation method. Int J Pharm 2007; 342: 26-32.
28. Brick MC, Palmer HJ, Whitesides TH. Formation of colloidal dispersions of organic materials in aqueous media by solvent shifting. Langmuir 2003; 19: 6367-80.
29. Wang X, Gillian JM, Kirwan DJ. Quasi-emulsion precipitation of pharmaceuticals. 1. Conditions for formation and crystal nucleation and growth behavior. Cryst Growth Des 2006; 6: 2214-27.
30. Haberkorn H, Franke D, Frechen T, Goesele W, Rieger J. Early stages of particle formation in precipitation reactions-quinacridone and boehmite as generic examples. J Colloid Interface Sci 2003; 259: 112-6.
31. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 1. inhibition of ostwald ripening. Langmuir 2006; 22: 906-10.
32. Matteucci ME, Hotze MA, Johnston KP, Williams RO. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 2006; 22: 8951-9.
33. Xia D, Wu JX, Cui F, et al. Solvent-mediated amorphous-tocrystalline transformation of nitrendipine in amorphous particle suspensions containing polymers. Eur J Pharm Sci 2012; 46: 446-54.
34. Matteucci ME, Paguio JC, Miller MA, Johnston KP. Highly Supersaturated Solutions from Dissolution of Amorphous Itraconazole Microparticles at pH 6.8. Mol Pharm 2009; 6: 375-85.
35. Cölfen H, Mann S. Higher-order organization by mesoscale selfassembly and transformation of hybrid nanostructures. Angew Chem Int Ed 2003; 42: 2350-65.
36. Threlfall T. Structural and thermodynamic explanations of Ostwald's Rule. Org Process Res Dev 2003; 7: 1017-27.
37. Zhang TH, Liu XY. How does a transient amorphous precursor template crystallization. J Am Chem Soc 2007; 129: 13520-6.
38. Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U. Amorphous drug nanosuspensions. 3. particle dissolution and crystal growth. Langmuir 2007; 23: 9866-9874.
39. Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 2005; 24: 67-75.
40. Li A, Yalkowsky SH. Predicting cosolvency. 2. correlation with solvent physicochemical properties. Ind Eng Chem Res 1998; 37: 4476-80.
41. Li A, Yalkowsky SH. Predicting cosolvency. 1. solubility ratio and solute log Kow. Ind Eng Chem Res 1998; 37: 4470-5.
42. Millard J, Alvarez-Nunez F, Yalkowsky S. Solubilization by cosolvents. Establishing useful constants for the log-linear model. Int J Pharm 2002; 245: 153-66.
43. Wang Z, Chen JF, Le Y, Shen ZG. Preparation of Ultrafine Beclomethasone Dipropionate Drug Powder by Antisolvent Precipitation. Ind Eng Chem Res 2007; 46: 4839-45.
44. Hu TT, Zhao H, Jiang LC, Le Y, Chen JF, Yun J. Engineering Pharmaceutical Fine Particles of Budesonide for Dry Powder Inhalation (DPI). Ind Eng Chem Res 2008; 47: 9623-7.
45. Zhang JY, Shen ZG, Zhong J, et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 2006; 323: 153-60.
46. Ma Q, Sun H, Che E, Zheng X, Jiang T, Sun C, Wang S. Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state. Int. J. Pharm 2012; In Press, Accepted Manuscript, doi:10.1016/j.ijpharm.2012.12.025.
47. Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur. J. Pharm. Sci 2007; 30: 367-74.
48. Xia D, Quan P, Piao H, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 2010; 40: 325-34.
49. Guo Z, Zhang M, Li H, Wang J, Kougoulos E. Effect of ultrasound on anti-solvent crystallization process. J. Cryst. Growth 2005; 273: 555-63.
50. Ji J-b, Lu X-h, Xu Z-c. Effect of ultrasound on adsorption of Geniposide on polymeric resin. Ultrason. Sonochem 2006; 13: 463-70.
51. Roelands CPM, Jiang S, Kitamura M, Horst JHt, Kramer HJM, Jansens PJ. Antisolvent crystallization of the polymorphs of LHistidine as a function of supersaturation ratio and of solvent composition. Cryst Growth Des 2006; 6: 955-63.
52. Nishida I. Precipitation of calcium carbonate by ultrasonic irradiation. Ultrason. Sonochem 2004; 11: 423-8.
53. Luque de Castro MD, Priego-Capote F. Ultrasound-assisted crystallization (sonocrystallization). Ultrason. Sonochem 2007; 14: 717-24.
54. Nalajala VS, Moholkar VS. Investigations in the physical mechanism of sonocrystallization. Ultrason. Sonochem 2011; 18: 345-55.
55. Kipp JE, Wong T, Chung J, et al. Method for preparing submicron particle suspensions, U. S Patent: 6884436 2005.
56. Werling J, Doty MJ, Rebbeck CL, Wong JCT, Kipp JE. Polymorphic form of itraconazole In: ed. eds.: U. S 2007.
57. Lindfors L, Forssn S, Skantze P, Skantze U, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 2. experimental determination of bulk monomer concentrations. Langmuir 2006; 22: 911-6.
58. Pokharkar VB, Malhi T, Mandpe L. Bicalutamide nanocrystals with improved oral bioavailability: in vitro and in vivo evaluation. Pharm Dev Technol 2012.
59. Liu D, Xu H, Tian B, et al. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. AAPS PharmSciTech 2012; 13: 295-304.
60. Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm 2008; 70: 109-15.
61. Dhumal RS, Biradar SV, Paradkar AR, York P. Particle engineering using sonocrystallization: Salbutamol sulphate for pulmonary delivery. Int J Pharm 2009; 368: 129-37.
62. Park MW, Yeo S-D. Antisolvent crystallization of carbamazepine from organic solutions. Chem Eng Res Des 2012.
63. Barlow DA, Baird JK, Su CH. Theory of the von Weimarn rules governing the average size of crystals precipitated from a supersaturated solution. J Cryst Growth 2004; 264: 417-23.
64. Ludwig FP, Schmelzer J. On von Weimarn's Law in Nucleation Theory. J Colloid Interface Sci 1996; 181: 503-10.
65. Baldyga J, Makowski L, Orciuch W. Interaction between mixing, chemical reactions, and precipitation. Ind. Eng. Chem. Res 2005; 44: 5342-52.
66. Zauner R, Jones AG. On the influence of mixing on crystal precipitation processes-application of the segregated feed model. Chem. Eng. Sci 2002; 57: 821-31.
67. Bell TA. Challenges in the scale-up of particulate processes-an industrial perspective. Powder Technol 2005; 150: 60-71.
68. Mahajan AJ, Kinvan DJ. Rapid precipitation of biochemicals. J Phys D Appl Phys 1993; 26: B176-B180.
69. Lehwald A, Janiga G, Thevenin D, Zahringer K. Simultaneous investigation of macro-and micro-mixing in a static mixer. Chem. Eng. Sci 2012; 79: 8-18.
70. Johnson BK, Prud'homme RK. Chemical processing and micromixing in confined impinging jets. AIChE J 2003; 49: 2264-82.
71. Bockhorn H, Mewes D, Peukert W, Warnecke H-J eds. Micro and Macro Mixing: Analysis, Simulation and Numerical Calculation. Springer, Verlag Berlin Heidelberg 2010.
72. Lehwald A, Thevenin D, Zahringer K. Quantifying macro-mixing and micro-mixing in a static mixer using two-tracer laser-induced fluorescence. Exp Fluids 2010; 48: 823-36.
73. Johnson BK. Flash nano-precipitation of organic actives via confined micromixing and block copolymer stabilization. Ph. D thesis of Princeton university 2003.
74. Siddiqui SW, Zhao Y, Kukukova A, Kresta SM. Characteristics of a confined impinging jet reactor: energy dissipation, homogeneous and heterogeneous reaction products, and effect of unequal flow. Ind. Eng. Chem. Res 2009; 48: 7945-58.
75. Demyanovich RJ, Bourne JR. Rapid micromixing by the impingement of thin liquid sheets. 2. Mixing study. Ind. Eng. Chem. Res 1989; 28: 830-9.
76. Villermaux J. The role of energy dissipation in contacting and mixing devices. Chern. Eng. Technol 1988; 11: 276-87.
77. Midler JM, L PE, F WE, Mauricio F, D LP, Jaanpyng H, Shih-Hsie P. Crystallization method to improve crystal structure and size US. Patent 5314506, 1994.
78. J AED, C CT, P WN. Reactive crystallization method to improve particle size, US. Patent 6558435 2003.
79. Dauer R, Mokrauer JE, McKeel WJ. Dual jet crystallizer apparatus, US. Patent 5578279, 1996.
80. Lindrud MD, Kim S, Wei C. Sonic impinging jet crystallization apparatus and process, US. Patent 6302958 2001.
81. Liu Y, Fox RO. CFD predictions for chemical processing in a confined impinging-jets reactor. AIChE J 2006; 52: 731-44.
82. Woo XY, Tan RBH, Braatz RD. Modeling and computational fluid dynamics-population balance equation-micromixing simulation of impinging jet crystallizers. Cryst Growth Des 2009; 9: 156-64.
83. Mahajan AJ, Kirwan DJ. Micromixing effects in a two-impingingjets precipitator. AIChE J 1996; 42: 1801-14.
84. Marchisio DL, Rivautella L, Barresi AA. Design and scale-up of chemical reactors for nanoparticle precipitation. AIChE J 2006; 52: 1877-87.
85. Lince F, Marchisio DL, Barresi AA. Strategies to control the particle size distribution of poly-ε-caprolactone nanoparticles for pharmaceutical applications. J Colloid Interface Sci 2008; 322: 505-15.
86. Johnson Brian K, Saad W, Prud'homme Robert K eds. Nanoprecipitation of Pharmaceuticals Using Mixing and Block Copolymer Stabilization, Polymeric Drug Delivery II. American Chemical Society 2006.
87. Johnson BK, Prud'homme RK. Flash NanoPrecipitation of organic actives and block copolymers using a confined impinging jets mixer. Aust J Chem 2003; 56: 1021-4.
88. Lince F, Marchisio DL, Barresi AA. Smart mixers and reactors for the production of pharmaceutical nanoparticles: Proof of concept. Chem Eng Res Des 2009; 87: 543-9.
89. Chiou H, Chan HK, Prud'homme RK, Raper JA. Evaluation on the use of confined liquid impinging jets for the synthesis of nanodrug particles. Drug Dev Ind Pharm 2008; 34: 59-64.
90. Chiou H, Chan HK, Heng D, Prud'homme RK, Raper JA. A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. J Aerosol Sci 2008; 39: 500-9.
91. III ROW, Watts AB, Miller DA eds. Formulating Poorly Water Soluble Drugs. Springer, New York Dordrecht Heidelberg London 2012.
92. Lindenberg C, Mazzotti M. Experimental characterization and multi-scale modeling of mixing in static mixers. Part 2. Effect of viscosity and scale-up. Chem Eng Sci 2009; 64: 4286-94.
93. Lindenberg C, Scholl J, Vicum L, Mazzotti M, Brozio J. Experimental characterization and multi-scale modeling of mixing in static mixers. Chem Eng Sci 2008; 63: 4135-49.
94. Choi YJ, Chung ST, Oh M, Kim HS. Investigation of crystallization in a jet Y-mixer by a hybrid computational fluid dynamics and process simulation approach. Cryst. Growth Des 2005; 5: 959-68.
95. Schwarzer WP. Experimental Investigation into the Influence of Mixing on Nanoparticle Precipitation. Chem Eng Technol 2002; 25: 657-61.
96. Ali HS, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009; 375: 107-13.
97. Ali HS, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. J Control Release 2011; 149: 175-81.
98. Zhao H, Wang JX, Wang QA, Chen JF, Yun J. Controlled Liquid Antisolvent Precipitation of Hydrophobic Pharmaceutical Nanoparticles in a Microchannel Reactor. Ind Eng Chem Res 2007; 46: 8229-35.
99. Gradl J, Schwarzer HC, Schwertfirm F, Manhart M, Peukert W. Precipitation of nanoparticles in a T-mixer: Coupling the particle population dynamics with hydrodynamics through direct numerical simulation. Chem Eng Process 2006; 45: 908-16.
100. Blandin AF, Mangin D, Nallet V, Klein JP, Bossoutrot JM. Kinetics identification of salicylic acid precipitation through experiments in a batch stirred vessel and a T-mixer. Chem Eng J 2001; 81: 91-100.
101. Panagiotou T, Mesite SV, Fisher RJ. Production of norfloxacin nanosuspensions using microfluidics reaction technology through solvent/antisolvent crystallization. Ind Eng Chem Res 2009; 48: 1761-71.
102. Schwarzer HC, Peukert W. Combined experimental/numerical study on the precipitation of nanoparticles. AIChE J 2004; 50: 3234-47.
103. Ståhl M, Åslund BL, Rasmuson ÅC. Reaction Crystallization Kinetics of Benzoic Acid. AIChE J 2001; 47: 1544-60.
104. Beck C, Dalvi SV, Dave RN. Controlled liquid antisolvent precipitation using a rapid mixing device. Chem Eng Sci 2010; 65: 5669-75.
105. Liu Z, Cheng Y, Jin Y. Fast Liquid Jet Mixing in Millimeter Channels with Various Multislits Designs. Ind Eng Chem Res 2008; 47: 9744-53.
106. Liu Y, Cheng C, Prud'homme RK, Fox RO. Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation. Chem Eng Sci 2008; 63: 2829-42.
107. D'Addio SM, Prud'homme RK. Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Delivery Rev 2011; 63: 417-26.
108. Bourne JR, Lenzner J, Petrozzi S. Micromixing in Static Mixers: An Experimental Study. Ind Eng Chem Res 1992; 31: 1216-22.
109. Alvarez AJ, Myerson AS. Continuous Plug Flow Crystallization of Pharmaceutical Compounds. Cryst Growth Des 2010; 10: 2219-28.
110. Douroumis D, Fahr A. Nano-and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique. Eur J Pharm Biopharm 2006; 63: 173-5.
111. Dong Y, Ng WK, Hu J, Shen S, Tan RB. A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. Int J Pharm 2010; 386: 256-61.
112. Hobbs DM, Muzzio FJ. The Kenics static mixer: a threedimensional chaotic flow. Chem Eng J 1997; 67: 153-66.
113. Hobbs DM, Muzzio FJ. Optimization of a static mixer using dynamical systems techniques. Chem Eng Sci 1998; 53: 3199-213.
114. Trachsel F, Gunther A, Khan S, Jensen KF. Measurement of residence time distribution in microfluidic systems. Chem Eng Sci 2005; 60: 5729-37.
115. Boskovic D, Lobbecke S, Gross A, Kohler M. Residence Time Distribution Studies in Microfluidic Mixing Structures. Chem Eng Technol 2011; 34: 361-70.
116. Edward L. Paul, Victor Atiemo-Oben, Kresta SM eds. Handbook of Industrial Mixing: Science and Practice. John Wiley & Sons, Inc.: Hoboken, New Jersey 2004.
117. Chen JF, Zhou MY, Shao L, et al. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm 2004; 269: 267-74.
118. Hu TT, Wang JX, Shen ZG, Chen JF. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particuology 2008; 6: 239-51.
119. Chen JF, Wang YH, Guo F, Wang XM, Zheng C. Synthesis of nanoparticles with novel technology: High-gravity reactive precipitation. Ind Eng Chem Res 2000; 39: 948-54.
120. Chen J-F, Zhang J-Y, Shen Z-G, Zhong J, Yun J. Preparation and Characterization of Amorphous Cefuroxime Axetil Drug Nanoparticles with Novel Technology: High-Gravity Antisolvent Precipitation. Ind Eng Chem Res 2006; 45: 8723-7.
121. Zhong J, Shen ZG, Yang Y, Chen JF. Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. Int J Pharm 2005; 301: 286-93.
122. Chiou H, Li L, Hu TT, Chan HK, Chen JF, Yun J. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int J Pharm 2007; 331: 93-8.
123. Tabernero A, Martín del Valle EM, Galán MA. Supercritical fluids for pharmaceutical particle engineering: Methods, basic fundamentals and modelling. Chemical Engineering and Processing: Process Intensification 2012; 60: 9-25.
124. Reverchon E, De Marco I, Torino E. Nanoparticles production by supercritical antisolvent precipitation: A general interpretation. J. Supercrit. Fluids 2007; 43: 126-38.
125. Reverchon E, De Marco I, Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation. Int J Pharm 2002; 243: 83-91.
126. Rantakyla M, Jantti M, Aaltonen O, Hurme M. The effect of initial drop size on particle size in the supercritical antisolvent precipitation (SAS) technique. J. Supercrit. Fluids 2002; 24: 251-63.
127. Villiers MMd, Aramwit P, Kwon GS eds. Nanotechnology in Drug Delivery. Springer Science: New York 2008.
128. Yang L, Sun Z, Zu Y, Zhao C, Sun X, Zhang Z, Zhang L. Physicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical anti-solvent (SAS) process. Food Chem 2012; 132: 319-25.
129. Reverchon E, De Marco I, Della Porta G. Tailoring of nano-and micro-particles of some superconductor precursors by supercritical antisolvent precipitation. J Supercrit Fluids 2002; 23: 81-7.
130. Varughese P, Li J, Wang W, Winstead D. Supercritical antisolvent processing of gamma-Indomethacin: Effects of solvent, concentration, pressure and temperature on SAS processed Indomethacin. Powder Technol 2010; 201: 64-9.
131. Reverchon E, De Marco I, Caputo G, Della Porta G. Pilot scale micronization of amoxicillin by supercritical antisolvent precipitation. J Supercrit Fluids 2003; 26: 1-7.
132. Montes A, Tenorio A, Gordillo MD, Pereyra C, Martínez de la Ossa EJ. Screening design of experiment applied to supercritical antisolvent precipitation of amoxicillin: Exploring new miscible conditions. J Supercrit Fluids 2010; 51: 399-403.
133. Vemavarapu C, Mollan MJ, Lodaya M, Needham TE. Design and process aspects of laboratory scale SCF particle formation systems. Int J Pharm 2005; 292: 1-16.
134. Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. Int J Pharm 2001; 228: 19-31.
135. Sanganwar GP, Gupta RB. Nano-mixing of dipyridamole drug and excipient nanoparticles by sonication in liquid CO2. Powder Technol 2009; 196: 36-49.
136. Park SJ, Choi SH, Yoon HH. Preparation of poly-lactic acid nano/microparticles using supercritical anti-solvent with enhanced mass transfer. J Industrial Engineering Chem 2010; 16: 101-5.
137. Jin H, Li S, Hu D, Zhao Y. Preparation of PLA-PEG nanoparticles by the solution enhanced dispersion with enhanced mass transfer using ultrasound in supercritical CO2. Powder Technol 2012; 227: 17-23.
138. Lee LY, Wang CH, Smith KA. Supercritical antisolvent production of biodegradable micro-and nanoparticles for controlled delivery of paclitaxel. J Control Release 2008; 125: 96-106.
139. Pathak P, Meziani MJ, Desai T, Sun YP. Nanosizing Drug Particles in Supercritical Fluid Processing. J Am Chem Soc 2004; 126: 10842-3.
140. Charoenchaitrakool M, Dehghani F, Foster NR, Chan HK. Micronization by rapid expansion of supercritical solutions to enhance the dissolution rates of poorly water-soluble pharmaceuticals. Ind Eng Chem Res 2000; 39: 4794-802.
141. Huang Z, Sun GB, Chiew YC, Kawi S. Formation of ultrafine aspirin particles through rapid expansion of supercritical solutions (RESS). Powder Technol 2005; 160: 127-34.
142. Thakur R, Gupta RB. Rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process: Formation of griseofulvin nanoparticles. Ind Eng Chem Res 2005; 44: 7380-7.
143. Thakur R, Gupta RB. Rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process: Formation of 2-aminobenzoic acid nanoparticle. J Supercrit Fluids 2006; 37: 307-15.
144. Pathak P, Meziani MJ, Sun YP. Supercritical fluid technology for enhanced drug delivery. Expert Opin Drug Deliv 2005; 2: 747-61.
145. Pathak P, Meziani MJ, Desai T, Sun YP. Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercrit. Fluids 2006; 37: 279-86.
146. Pathak P, Meziani MJ, Desai T, Foster C, Diaz JA, Sun YP. Supercritical fluid processing of drug nanoparticles in stable suspension. J Nanosci Nanotechnol 2007; 7: 2542-5.
147. Pathak P, Prasad GL, Meziani MJ, Joudeh AA, Sun YP. Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation. Langmuir 2007; 23: 2674-9.
148. Dalvi SV, Azad MA, Dave R. Precipitation and stabilization of ultrafine particles of Fenofibrate in aqueous suspensions by RESOLV. Powder Technol 2012; In Press, doi:10.1016/j.powtec.2012.05.038.
149. Türk M, Bolten D. Formation of submicron poorly water-soluble drugs by rapid expansion of supercritical solution (RESS): Results for Naproxen. J Supercrit Fluids 2010; 55: 778-85.
150. C.-J. Kim, Surface chemistry and colloids, Advanced pharmaceutics: physicochemical principles, CRC Press 2004; pp. 193-256.
151. MTH Nutan, Reddy IK. General principles of suspensions, in: A.K. Kulshreshtha, O.N. Singh, G.M. Wall (Eds.), Pharmaceutical suspensions: from formulation development to Manufacturing, Springer 2009, pp. 50.
152. Florence AT, Attwood D eds. Physicochemical Principles of Pharmacy (Fourth edition). Pharmaceutical Press: London Chicago 2006.
153. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011; 63: 456-69.
154. Welin-Berger K, Bergenstahl B. Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. Int J Pharm 2000; 200: 249-60.
155. Kulshreshtha AK, Singh ON, Wall GM eds. Pharmaceutical Suspensions: From Formulation Development to Manufacturing. Springer 2009.
156. Kawakami K. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Delivery Rev 2012; 64: 480-95.
157. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm 1998; 160: 229-37.
158. Johnson KC. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. J Pharm Sci 2012; 101: 681-9.
159. Jinno Ji, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly watersoluble drug, cilostazol, in beagle dogs. J. Control. Release 2006; 111: 56-64.
160. J. Swarbrick, J. Rubino, O. Rubino, Coarse dispersion, in: A. Gennaro (Ed.), Remington: The Science and Practice of Pharmacy 20th Ed., Lippincott Williams & Wilkins, Baltimore 2000, p. 322.
161. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18: 113-20.
162. Feldmann G, Fabrim ZE, Hennig GL. Ostwald Ripening of precipitates and self similarity of size distributions in reaction controlled growth. J. Mater. Sci 2008; 43: 614-20.
163. Derjaguin B, Landau L. Theory of the Stability of Strongly Charged Lyophobic Sols and of the Adhesion of Strongly Charged-Particles in Solutions of Electrolytes. Prog Surf Sci 1993; 43: 30-59.
164. Kim C-J ed. Advanced pharmaceutics: physicochemical principles. CRC Press 2004.
165. Mishra PR, Al Shaal L, Muller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm 2009; 371: 182-9.
166. Lee J, Kim M, Hong CK, Shim SE. Measurement of the dispersion stability of pristine and surface-modified multiwalled carbon nanotubes in various nonpolar and polar solvents. Meas. Sci. Technol 2007; 18: 3707-12.
167. Starov VM ed. Nanoscience: Colloidal and Interfacial Aspects. CRC Press 2010.
168. Pongpeerapat A, Wanawongthai C, Tozuka Y, Moribe K, Yamamoto K. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int J Pharm 2008; 352: 309-16.
169. Sugimoto T. Monodispersed Particles. Elsevier Science B.V.: Amsterdam-London-New York-Oxford-Paris-Shannon-Tokyo 2001.
170. Sugimoto T, Yamaguchi G. Contact recrystallization of silver halide microcrystals in solution. J. Cryst. Growth, 1976; 34: 253-62.
171. Xia D, Ouyang M, Wu JX, et al. Polymer-mediated anti-solvent crystallization of nitrendipine: monodispersed spherical crystals and growth mechanism. Pharm. Res 2012; 29: 158-69.
172. Zhang X, Xia Q, Gu N. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm 2006; 32: 857-63.
173. Wolde PRt, Frenkel D. Enhancement of protein crystal nucleation by critical density fluctuations. Science 1997; 277: 1975-8.
174. Petsev DN, Chen K, Gliko O, Vekilov PG. Diffusion-limited kinetics of the solution-solid phase transition of molecular substances. PNAS 2003; 100: 792-6.
175. Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 2006; 95: 2692-705.
176. Wu JX, Xia DN, van den Berg F, et al. A novel image analysis methodology for online monitoring of nucleation and crystal growth during solid state phase transformations. Int J Pharm 2012; 433: 60-70.
177. Pu X, Sun J, Wang Y, et al. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm 2009; 379: 167-73.
178. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113: 151-70.
179. Gao L, Liu GY, Wang XQ, Liu F, Xu YF, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm 2011; 404: 231-7.
180. Alonzo DE, Raina S, Zhou D, Gao Y, Zhang GGZ, Taylor LS. Characterizing the Impact of Hydroxypropylmethyl Cellulose on the Growth and Nucleation Kinetics of Felodipine from Supersaturated Solutions. Cryst. Growth Des 2012; 12: 1538-47.
181. Thorat AA, Dalvi SV. Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: Recent developments and future perspective. Chem Eng J 2012; 181: 1-34.
182. Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci 2011; 100: 3365-73.
183. Eerdenbrugh BV, Vermant J, Martens JA, et al. A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci 2008; 98: 2091-103.
184. Choi J-Y, Yoo JY, Kwak H-S, Nam BU, Lee J. Role of polymeric stabilizers for drug nanocrystal dispersions Current Applied Physics 2005; 5: 472-4.
185. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J. Pharm. Pharmacol 2010; 62: 1569-79.
186. Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res 2008; 10: 845-62.
187. Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: Effects on physicochemical properties. Eur. J. Pharm. Biopharm 2009; 71: 109-16.
188. Xie SY, Poornachary SK, Chow PS, Tan RBH. Direct Precipitation of Micron-Size Salbutamol Sulfate: New Insights into the Action of Surfactants and Polymeric Additives. Cryst. Growth Des 2010; 10: 3363-71.
189. Ilevbare GA, Liu HY, Edgar KJ, Taylor LS. Understanding polymer properties important for crystal growth inhibition-impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des 2012; 12: 3133-43.
190. Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci 2005; 24: 441-9.
191. Deng J, Leaf Huang FL. Understanding the structure and stability of paclitaxel nanocrystals. Int. J. Pharm 2010; 390: 242-9.
192. Beck C, Sievens-Figueroa L, Gärtner K, et al. Effects of stabilizers on particle redispersion and dissolution from polymer strip films containing Liquid Antisolvent precipitated griseofulvin particles. Powder Technol 2012; In Press, doi:10.1016/j.powtec.2012.05.047.
193. Ain-Ai A, Gupta PK. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int J Pharm 2008; 351: 282-8.
194. Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997; 277: 1232-7.
195. Bantchev G, Lu Z, Lvov Y. Layer-by-layer nanoshell assembly on colloids through simplified washless process. J. Nanosci. Nanotechnol 2009; 9: 396-403.
196. de Villiers MM, Otto DP, Strydom SJ, Lvov YM. Introduction to nanocoatings produced by layer-by-layer (LbL) self-assembly. Adv Drug Deliv Rev 2011; 63: 701-15.
197. Agarwal A, Lvov Y, Sawant R, Torchilin V. Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology. J. Control. Release 2008; 128: 255-60.
198. Quan P, Shi K, Piao HZ, Piao HY, Liang N, Xia DN, Cui FD. A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. Int J Pharm 2012; 430: 366-71.
199. Zheng Z, Zhang X, Carbo D, Clark C, Nathan C, Lvov Y. Sonication-assisted synthesis of polyelectrolyte-coated curcumin nanoparticles. Langmuir 2010; 26: 7679-81.
200. Fuhrmann K, Schulz JD, Gauthier MA, Leroux JC. PEG nanocages as non-sheddable stabilizers for drug danocrystals. ACS Nano 2012; 6: 1667-76.
201. Blagden N, Davey RJ. Polymorph selection: challenges for the future. Cryst. Growth Des 2003; 3: 873-85.
202. Brittain HG ed. Polymorphism in Pharmaceutical Solids (Second Edition). Informa Healthcare USA, Inc.: New York 2009.
203. Murphy D, Rodriguez-Cintron F, Langevin B, Kelly RC, Rodriguez-Hornedo N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int. J. Pharm 2002; 246: 121-34.
204. Gu CH, Young V, Jr., Grant DJ. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci 2001; 90: 1878-90.
205. Blagden N, Davey RJ, Lieberman HF, et al. Crystal chemistry and solvent effects in polymorphic systems-Sulfathiazole. J Chem Soc Faraday T, 1998; 94: 1035-44.
206. Pasquali I, Bettini R, Giordano F. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Delivery Rev 2008; 60: 399-410.
207. Gosselin PM, Thibert R, Preda M, McMullen JN. Polymorphic properties of micronized carbamazepine produced by RESS. Int J Pharm 2003; 252: 225-33.
208. Bettini R, Bonassi L, Castoro V, et al. Solubility and conversion of carbamazepine polymorphs in supercritical carbon dioxide. Eur. J. Pharm. Sci 2001; 13: 281-6.
209. Rustichelli C, Gamberini G, Ferioli V, Gamberini MC, Ficarra R, Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal 2000; 23: 41-54.
210. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 2008; 35: 127-35.
211. Kumar MP, Rao YM, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Current Nanoscience 2008; 4: 53-8.
212. Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: A case study. Pharm. Res 2008; 25: 2302-8.
213. Quan P, Xia DN, Piao HZ, et al. Nitrendipine Nanocrystals: Its Preparation, Characterization, and In vitro-In vivo Evaluation. AAPS PharmSciTech 2011; 12: 1136-43.
214. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005; 299: 167-77.
215. deChasteigner S, Cave G, Fessi H, Devissaguet JP, Puisieux F. Freeze-drying of itraconazole-loaded nanosphere suspensions: A feasibility study. Drug Dev. Res 1996; 38: 116-24.
216. Lee J, Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J. Control. Release 2006; 111: 185-92.
217. Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): Formulation and process optimization. Int. J. Pharm 2006; 309: 178-88.
218. Rogers TL, Gillespie IB, Hitt JE, et al. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm. Res 2004; 21: 2048-57.
219. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm 1997; 148: 47-54.
220. Matteucci ME, Brettmann BK, Rogers TL, Elder EJ, Williams RO, Johnston KP. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol. Pharm 2007; 4: 782-93.
221. Layre AM, Couvreur P, Richard J, Requier D, Ghermani NE, Gref R. Freeze-drying of composite core-shell nanoparticles. Drug Dev. Ind. Pharm 2006; 32: 839-46.